Business Description
Meta Biomed Co Ltd
NAICS : 339112
SIC : 3841
ISIN : KR7059210005
Compare
Compare
Traded in other countries / regions
059210.Korea IPO Date
2008-04-15Description
Meta Biomed Co Ltd manufactures and markets suture and dental supplies. The company's dental products include endodontic materials, restorative materials, and bone graft material, as well as equipment, including Endo motor, and Endo System. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics and incontinence meshs; bone products consisting of bone substitutes and cement; and medical products, including endoscope and ultrasonic products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.38 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.64 | |||||
| Debt-to-EBITDA | 3.1 | |||||
| Interest Coverage | 4.64 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.23 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.8 | |||||
| 3-Year EBITDA Growth Rate | 119 | |||||
| 3-Year EPS without NRI Growth Rate | 113.3 | |||||
| 3-Year Book Growth Rate | 13.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.91 | |||||
| 9-Day RSI | 51.76 | |||||
| 14-Day RSI | 48.52 | |||||
| 6-1 Month Momentum % | 21.75 | |||||
| 12-1 Month Momentum % | 104.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | |||||
| Quick Ratio | 0.78 | |||||
| Cash Ratio | 0.38 | |||||
| Days Inventory | 121.37 | |||||
| Days Sales Outstanding | 63.5 | |||||
| Days Payable | 21.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.47 | |||||
| Dividend Payout Ratio | 0.04 | |||||
| 3-Year Dividend Growth Rate | 26 | |||||
| Forward Dividend Yield % | 0.47 | |||||
| 5-Year Yield-on-Cost % | 1.12 | |||||
| Shareholder Yield % | -4.43 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.72 | |||||
| Operating Margin % | 12.93 | |||||
| Net Margin % | 12.13 | |||||
| FCF Margin % | -1.54 | |||||
| ROE % | 15.33 | |||||
| ROA % | 7.96 | |||||
| ROIC % | 12.24 | |||||
| ROC (Joel Greenblatt) % | 13.25 | |||||
| ROCE % | 12.41 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.97 | |||||
| PE Ratio without NRI | 8.81 | |||||
| Shiller PE Ratio | 100.78 | |||||
| Price-to-Owner-Earnings | 25.9 | |||||
| PEG Ratio | 0.64 | |||||
| PS Ratio | 1.21 | |||||
| PB Ratio | 1.39 | |||||
| Price-to-Tangible-Book | 1.43 | |||||
| Price-to-Operating-Cash-Flow | 9.87 | |||||
| EV-to-EBIT | 12.41 | |||||
| EV-to-EBITDA | 8.75 | |||||
| EV-to-Revenue | 1.52 | |||||
| EV-to-FCF | -97.32 | |||||
| Price-to-Projected-FCF | 8.89 | |||||
| Price-to-Median-PS-Value | 0.99 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.53 | |||||
| Price-to-Graham-Number | 0.75 | |||||
| Earnings Yield (Greenblatt) % | 8.06 | |||||
| FCF Yield % | -1.31 | |||||
| Forward Rate of Return (Yacktman) % | 16.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Meta Biomed Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 83,100.722 | ||
| EPS (TTM) (â‚©) | 429 | ||
| Beta | 1.24 | ||
| Volatility % | 93.38 | ||
| 14-Day RSI | 48.52 | ||
| 14-Day ATR (â‚©) | 162.593716 | ||
| 20-Day SMA (â‚©) | 4217 | ||
| 12-1 Month Momentum % | 104.13 | ||
| 52-Week Range (â‚©) | 2120 - 5570 | ||
| Shares Outstanding (Mil) | 22.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Meta Biomed Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Meta Biomed Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Meta Biomed Co Ltd Frequently Asked Questions
What is Meta Biomed Co Ltd(XKRX:059210)'s stock price today?
The current price of XKRX:059210 is â‚©4280.00. The 52 week high of XKRX:059210 is â‚©5570.00 and 52 week low is â‚©2120.00.
When is next earnings date of Meta Biomed Co Ltd(XKRX:059210)?
The next earnings date of Meta Biomed Co Ltd(XKRX:059210) is .
Does Meta Biomed Co Ltd(XKRX:059210) pay dividends? If so, how much?
The Dividend Yield %  of Meta Biomed Co Ltd(XKRX:059210) is 0.47% (As of Today), Highest Dividend Payout Ratio of Meta Biomed Co Ltd(XKRX:059210) was 0.24. The lowest was 0.04. And the median was 0.14. The  Forward Dividend Yield % of Meta Biomed Co Ltd(XKRX:059210) is 0.47%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers